Warnyta Minnaard
20-04-2023
If the practitioner doesn’t know where the primary tumor is located, they cannot offer a targeted treatment plan, and nor can they give the patient an estimate of their life expectancy.
Back to newsMore news
Screening for T cells that already fight the tumor: Hartwig’s pipeline in practice
16-07-2024
By Laura Nederveen In the search for more effective cancer treatments, Alena Gros and her team at Vall d’Hebron Institute …
Whole genome sequencing: the future of molecular diagnostics in gynecological cancer?
30-09-2025
To mark Gynecological Oncology Awareness Month, we spoke with oncologist Eelke Gort about the role of molecular diagnostics in these …
Biomarkers Reveal Which Cancer Patients Won’t Benefit From Treatment
25-06-2026
Researchers from Vall d’Hebron Institute of Oncology identify genomic signals predicting non-response to cancer therapies in collaboration with Hartwig Medical …
The complete DNA test is an important step toward treating forms of cancer that currently cannot be treated with targeted drugs.
Patient